Acting Attorney General Todd Blanche has reclassified marijuana as a Schedule III drug, a significant change to federal drug policy. This decision is anticipated to encourage research, provide tax benefits to businesses, and potentially influence state laws.

Federal Reclassification Explained

The reclassification, formalized on Thursday, moves marijuana from Schedule I – alongside drugs like heroin – to Schedule III, aligning it with substances such as ketamine and Tylenol with codeine. This change does not legalize recreational marijuana federally, but it opens doors for expanded research and eases restrictions on studying the drug’s effects.

Rationale Behind the Decision

Todd Blanche explained the move on social media, stating it will facilitate more focused research into marijuana’s safety and effectiveness, broadening patient access and providing healthcare professionals with more information. The Drug Enforcement Administration (DEA) is now required to hold administrative hearings before a judge to validate the rule change.

Years of Attempts and Recent Developments

Re-evaluating marijuana’s classification has been a recurring effort across multiple presidential administrations. President Joe Biden initiated a renewed effort, but it remained incomplete. Previous attempts faced challenges, with critics citing perceived hesitancy from former DEA Administrator Anne Milgram.

A subsequent executive order by President Donald Trump in December directed the Justice Department to expedite the process. Trump publicly expressed dissatisfaction with the slow pace, reportedly telling podcaster Joe Rogan he was being “slow walked.” Pressure from the cannabis industry also increased.

Economic and Research Implications

Experts predict the rescheduling will encourage state lawmakers to advance cannabis legislation. A key benefit is the potential removal of cannabis businesses from the constraints of Internal Revenue Code Section 280E.

Tax Relief and Economic Growth

Section 280E prevents businesses dealing with Schedule I or II substances from deducting standard business expenses. Brian Vicente, of Vicente LLP, estimates this change could unlock billions in economic activity and create tens of thousands of jobs. According to Whitney Economics, cannabis businesses have paid an estimated $15 billion in excess taxes due to 280E since 2018.

The rescheduling is also expected to accelerate medical research, as universities and hospitals will be less hesitant to conduct studies due to federal restrictions.